Hutchinson–Gilford Progeria Syndrome : From LMNA Mutation to Premature

Hutchinson–Gilford Progeria Syndrome : From LMNA Mutation to Premature

• 1.
  RARE DISEASE •NUCLEAR ARCHITECTURE • CELLULAR AGING Hutchinson–Gilford Progeria Syndrome From LMNA Mutation to Premature Cellular Aging Prepared by : Rangin A. Ghafwr
• 2.
  HGPS • SCIENTIFICOVERVIEW What is Progeria? A segmental premature-aging disorder caused by a toxic form of lamin A protien-progerin. Early onset. Children are typically healthy at birth; growth failure and distinctive physical findings emerge during the first year of life. Selective vulnerability. Skin, bone, connective tissue, and especially arteries are affected, while motor and intellectual development are generally preserved. Molecular clue. The abnormal lamin A protein, progerin, destabilizes the nuclear lamina and accelerates cellular decline. A single splicing error can disrupt the cell’s mechanical and genomic control center. Progerin-driven disruption of the nuclear envelope is the molecular hallmark of HGPS. Sources: [1] GeneReviews® (2025) • [2] StatPearls (2025) 1
• 3.
  HGPS • SCIENTIFICOVERVIEW Epidemiology & Rarity Ultra-rare in frequency; globally important for what it reveals about nuclear biology and vascular aging. ESTIMATED INCIDENCE 1 in 4 million Reported estimate at live birth in a pivotal clinical-trial publication. ESTIMATED PREVALENCE 1 in 20 million Commonly cited estimate for living individuals with HGPS. ORIGIN OF THE VARIANT ≈98% de novo Usually autosomal dominant; parental gonadal mosaicism explains a small minority. Estimates vary by study design, case ascertainment, and whether incidence or living prevalence is measured. Rare does not mean biologically unimportant. Sources: [1] GeneReviews® (2025) • [3] Gordon et al., JAMA (2018) 2
• 4.
  HGPS • CLINICALPHENOTYPE Clinical Features A coherent phenotype across skin, bone, connective tissue, and arteries—without loss of cognition. Growth & body composition Profound growth failure, low weight, lipoatrophy, and failure to thrive. Skin & hair Tight or scleroderma-like skin, alopecia, visible veins, and nail dystrophy. Craniofacial & dental Large cranium relative to face, micrognathia, narrow nasal tip, delayed dentition. Vascular & neurologic Accelerated atherosclerosis, myocardial infarction, stroke; cognition usually normal. Multisystem, but not global, premature aging Musculoskeletal system Joint contractures, coxa valga, hip dislocation, and skeletal dysplasia limit mobility. The most life-limiting pathology is vascular—not cognitive. Sources: [1] GeneReviews® (2025) • [2] StatPearls (2025) • [3] Gordon et al., JAMA (2018) 3
• 5.
  HGPS • PHYSIOLOGICALIMPACT Physiological Impact of HGPS HGPS is multisystem disease, but the most life-limiting physiology is vascular. Cardiovascular Arterial stiffness, accelerated atherosclerosis, and vascular smooth-muscle-cell dysfunction drive myocardial infarction and stroke risk. Musculoskeletal Reduced bone mineralization, skeletal dysplasia, joint contractures, and progressive mobility limitation. Metabolic / adipose Severe loss of subcutaneous fat, abnormal body composition, low body weight, and profound growth failure. Nervous system Cognitive development is generally preserved; neurological injury is mainly secondary to vascular disease, especially stroke. A systemic phenotype with selective tissue vulnerability. Sources: [1] GeneReviews® (2025) • [2] StatPearls (2025) • [3] Gordon et al., PNAS (2012) • [5] Gonzalo et al. (2016) 4
• 6.
  HGPS • CARDIOVASCULARPHYSIOLOGY Vascular Aging Is the Central Physiological Threat Mechanical stress, cellular dysfunction, and vascular events form one connected disease pathway. 1 • Vascular mechanics Progressive arterial stiffness changes pulse- wave transmission and increases the mechanical load on vulnerable vessels. 2 • Vascular cells Endothelial and vascular smooth-muscle function become abnormal; smooth-muscle cells may be lost or dysfunctional. 3 • Clinical events Accelerated atherosclerosis raises the risk of myocardial infarction and stroke; cardiac electrical or functional abnormalities may also occur. More compliant vessel Stiffened, plaque-laden vessel Arterial stiffness → atherosclerosis → vascular occlusion → myocardial infarction / stroke Cardiovascular disease is the major threat to survival. Sources: [1] GeneReviews® (2025) • [2] StatPearls (2025) • [3] Gordon et al., PNAS (2012) • [4] Gordon et al., JAMA (2018) • [5] Gonzalo et al. (2016) 5
• 7.
  HGPS • MUSCULOSKELETAL& METABOLIC PHYSIOLOGY Growth Failure Reflects Altered Tissue Biology Bone, connective tissue, and adipose tissue are all affected by the same nuclear-stress biology. MUSCULOSKELETAL Reduced mineralization Skeletal dysplasia, coxa valga and hip problems, joint contractures. METABOLIC / ADIPOSE Severe lipoatrophy Abnormal body composition, low body weight, and profound growth failure—not simply lack of caloric intake. The same nuclear-stress biology reshapes both the skeleton and the body’s energy-storage tissues. Sources: [1] GeneReviews® (2025) • [2] StatPearls (2025) • [3] Gordon et al., PNAS (2012) • [5] Gonzalo et al. (2016) 6
• 8.
  HGPS • NERVOUSSYSTEM The Brain Is Not the Primary Target HGPS does not cause global neurological aging; the cerebral circulation is the major route to neurologic injury. Cognition generally preserved. Intellectual development is usually not the primary site of disease. Motor development often intact early. Mobility later becomes limited mainly by skeletal and joint disease. Neurologic injury is mainly secondary. Stroke can produce deficits when accelerated vascular disease reaches the brain. Cognition preserved Stroke cerebrovascular injury The brain is not the primary target—the cerebral circulation is. Sources: [1] GeneReviews® (2025) • [2] StatPearls (2025) • [4] Gordon et al., JAMA (2018) 7
• 9.
  HGPS • GENETICORIGIN LMNA Gene A synonymous coding change becomes a high-impact splicing mutation. SIMPLIFIED LMNA EXON MAP • NOT TO SCALE 1 2 3 4 5 6 7 8 9 10 11 12 EXON 11 CODON-LEVEL READING c.1824C>T → p.Gly608Gly The amino acid is unchanged—so the variant appears “silent” in the protein code. RNA-LEVEL CONSEQUENCE Cryptic splice donor activated Exon 11 is misread, creating a truncated lamin A precursor that becomes progerin. Same DNA letter code. Different RNA decision. Sources: [1] GeneReviews® (2025) • [5] Gonzalo et al., Ageing Res Rev (2016) 8
• 10.
  HGPS • NUCLEARARCHITECTURE Lamin A & Nuclear Architecture The nuclear lamina is a structural scaffold—and a regulator of genome organization and cellular signaling. Mechanical support Lamin A/C helps the nucleus resist deformation and couples physical forces to cell behavior. Genome organization It anchors chromatin at the nuclear periphery, shaping transcriptional programs and DNA transactions. Nuclear signaling Lamina interactions influence gene expression, replication, DNA repair, and mechanotransduction. ORDERLY LAMINA HGPS-LIKE STRESS Conceptual illustration: smooth nuclear geometry contrasts with blebbing, lamina disruption, and chromatin disorganization. When the lamina fails, structure, genome regulation, and force sensing fail together. Sources: [5] Gonzalo et al., Ageing Res Rev (2016) • [6] Cao et al., J Clin Invest (2011) 9
• 11.
  HGPS • CAUSALBIOLOGY The Molecular Mechanism One altered RNA-processing decision initiates a cascade from nuclear damage to premature tissue aging. 1 LMNA c.1824C>T Activates a cryptic splice site in exon 11. 2 Aberrant splicing Removes 150 nucleotides / 50 amino acids from prelamin A. 3 ZMPSTE24 site lost The farnesyl tail cannot be removed from progerin. 4 Progerin accumulates Persistent membrane anchoring distorts the nuclear lamina. 5 Nuclear stress Chromatin disruption, DNA damage, senescence, and tissue injury. Large arteries are particularly vulnerable because vascular cells face chronic mechanical stress and depend on durable nuclear architecture. Sources: [3] Gordon et al., JAMA (2018) • [5] Gonzalo et al. (2016) • [6] Cao et al. (2011) 10
• 12.
  HGPS • PROTEINPROCESSING Progerin Formation The missing cut leaves a permanent molecular anchor at the inner nuclear membrane. NORMAL PRELAMIN A MATURATION 1. CAAX farnesylation targets prelamin A to the nuclear envelope. 2. Trimming and carboxymethylation prepare the precursor. 3. ZMPSTE24 removes the farnesylated terminal tail. Mature lamin A: mobile scaffold HGPS PROGERIN PATHWAY 1. Cryptic splicing deletes 50 amino acids from prelamin A. 2. The ZMPSTE24 cleavage site is missing. 3. The farnesyl tail is retained: persistent membrane anchoring. Progerin: toxic accumulation Lonafarnib blocks farnesyltransferase downstream; it reduces membrane association but does not correct the LMNA mutation. Sources: [5] Gonzalo et al. (2016) • [6] Cao et al. (2011) • [9] DailyMed ZOKINVY label (2024) 11
• 13.
  HGPS • CELLULARAGING Cellular Consequences A stressed nucleus becomes a senescent cell through mutually reinforcing structural, epigenetic, and DNA-damage pathways. Nuclear morphology Blebbing, herniations, thickened lamina. Chromatin Heterochromatin loss, altered histone marks. Genome maintenance DNA damage , genomic dysfunction, telomere dysfunction. Cell fate & tissue injury ROS, mitochondrial dysfunction, and senescence. Progerin is also produced at low levels in normal cells; telomere dysfunction can amplify progerin-associated senescence pathways. Sources: [5] Gonzalo et al. (2016) • [6] Cao et al. (2011) • [7] J Clin Invest cellular-senescence study 12
• 14.
  HGPS • CAUSALPATHWAY From LMNA Mutation to Premature Mortality A single splicing defect can propagate from nuclear architecture to life-threatening vascular disease. LMNA c.1824C>T Cryptic splice-site activation Abnormal prelamin A processing Progerin Persistent farnesylation Nuclear-envelope deformation Chromatin & DNA damage Cellular senescence Vascular smooth- muscle dysfunction Accelerated atherosclerosis Myocardial infarction From an altered splice decision to a vascular event: one connected biological cascade. Sources: [1] GeneReviews® (2025) • [5] Gonzalo et al. (2016) • [6] Cao et al. (2011) 13 stroke
• 15.
  HGPS • PROGNOSIS LifeExpectancy in HGPS Median survival is approximately 14.6 years—but individual trajectories vary considerably. MEDIAN SURVIVAL ≈14.6 years A population statistic—not a prediction for one individual. MAIN CAUSE OF DEATH Cardiovascular disease Myocardial infarction / Stroke Other severe vascular complications ~6 years median ≈14.6 years ~20 years Typical reported range: approximately 6–20 years Reported survival varies by cohort, treatment exposure, and ascertainment. Sources: [1] GeneReviews® (2025) • [2] StatPearls (2025) • [4] Gordon et al., JAMA (2018) 14
• 16.
  HGPS • CLINICALTRAJECTORY HGPS in Real Life: A Clinical Example A de-identified representative trajectory—not a single patient record—shows how the phenotype emerges over time. Birth — appears generally healthy Early infancy may not yet reveal the disorder. 6–12 months — growth failure becomes noticeable Weight gain and linear growth begin to lag behind peers. 1–3 years — phenotype becomes recognizable Alopecia, loss of subcutaneous fat, skin changes, and characteristic facial features emerge. Childhood — skeletal and vascular disease progresses Joint contractures, skeletal abnormalities, and progressive vascular dysfunction limit physiology. Later childhood / adolescence — cardiovascular risk rises Major complications may include myocardial infarction or stroke. Images show two individuals with HGPS; they do not represent a longitudinal case. Clinical clue: normal development + severe growth failure + lipoatrophy + alopecia + tight skin + characteristic facial features should raise suspicion for HGPS. Sources: [1] GeneReviews® (2025) • [2] StatPearls (2025) • [3] Gordon et al., PNAS (2012) • Clinical image: MedlinePlus Genetics, NIH/NLM 15
• 17.
  HGPS • CLINICALRECOGNITION Diagnosis Clinical pattern first—molecular confirmation closes the loop and enables targeted management. 1. Recognize Growth failure, lipoatrophy, alopecia, skin, joint, and craniofacial clues. 2. Confirm Sequence LMNA for c.1824C>T or other progerin-producing variants. 3. Differentiate Separate HGPS from Werner syndrome and other progeroid laminopathies. 4. Monitor Coordinate cardiovascular, neurologic, skeletal, dental, eye, hearing, and nutrition care. Diagnostic question HGPS clue When does it emerge? Usually within the first year of life, commonly at 6–12 months. What confirms it? A heterozygous LMNA variant that produces progerin. What is generally preserved? Motor and mental development are typically normal. What demands surveillance? Atherosclerosis, stroke, heart failure, growth, skeletal, dental, eye, and hearing complications. Sources: [1] GeneReviews® (2025) • [2] StatPearls (2025) 16
• 18.
  HGPS • CURRENTMANAGEMENT Current Treatment Lonafarnib changes the trajectory for many patients—but does not correct the mutation or cure HGPS. Lonafarnib (ZOKINVY) FDA-approved farnesyltransferase inhibitor • Initial U.S. approval 2020 Indication: reduces risk of mortality in HGPS for labeled patients aged ≥12 months with BSA ≥0.39 m². Evidence: can improve arterial stiffness, weight gain, skeletal measures, and hearing in subsets of patients. Limit: lipodystrophy, alopecia, skin findings, and joint contractures may persist. Matched-cohort mortality after median 2.2 years Mortality 0 5 10 15 20 25 30 35 40 3.7% 33.3% Lonafarnib Matched untreated Mortality (%) Observational matched-cohort analysis ; not lifetime mortality.. Surveillance Cardiovascular and neurologic monitoring are central. Function & nutrition PT/OT, mobility, dental, hearing, eye, skin, and nutrition care. Safety monitoring GI effects, interactions, ECG, labs, renal and ophthalmic monitoring. Sources: [1] GeneReviews® (2025) • [3] Gordon et al., PNAS (2012) • [4] Gordon et al., JAMA (2018) • [9] DailyMed label (2024) 17
• 19.
  HGPS • TRANSLATIONALFRONTIER Research & Future Therapies The field is moving from moderating progerin toxicity toward suppressing, editing, or correcting its source. Reduce Antisense oligonucleotides. Correct Base editing. Block Progerin membrane interaction. Molecular correction is an aspiration—not yet a proven human therapy. HGPS reveals a general principle: nuclear architecture is not passive—it is a determinant of cellular aging. SELECTED REFERENCES [1] GeneReviews® (2025). HGPS. NCBI Bookshelf. [3] Gordon et al. PNAS. 2012;109:16666–16671. doi:10.1073/pnas.1202529109 [4] Gordon et al. JAMA. 2018;319:1687–1695. doi:10.1001/jama.2018.3264 [5] Gonzalo et al. Ageing Res Rev. 2016;33:18–29. doi:10.1016/j.arr.2016.06.007 [6] Cao et al. J Clin Invest. 2011;121:2833–2844. doi:10.1172/JCI43578 [8] Puttaraju et al. Nat Med. 2021;27:526–535. doi:10.1038/s41591-021-01262-4 [9] DailyMed. ZOKINVY (lonafarnib) label, 2024. [10] Koblan et al. Nature. 2021;589:608–614. doi:10.1038/s41586-020-03086-7 • [11] NCT06775041, ClinicalTrials.gov (updated 2026-02-09) Sources: [5] [8] [10] [11] • Full references are provided above. 18
• 20.
  THANK YOU Thank youfor reading! For more presentations on Genetics, Cancer Biology & Biomedical Science follow my profile. Genetics • Cancer Biology • Biomedical Science